Quantisnow Logo
Dashboard

SEC Form SC 13G filed by Adagene Inc.

$ADAG
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ADAG alert in real time by email
SC 13G 1 eh220223350_13g-adagene.htm SCHEDULE 13G

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

 

(Amendment No. )*

 

Adagene Inc.

(Name of Issuer)
 

Ordinary shares, par value US$0.0001 per share

(Title of Class of Securities)
 

005329107**

(CUSIP Number)
 

December 31, 2021

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  ☐ Rule 13d-1(b)
  ☐ Rule 13d-1(c)
  ☒ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

**This CUSIP applies to the American Depositary Shares, evidenced by American Depositary Receipts, each representing one and one quarter (1.25) ordinary shares. No CUSIP has been assigned to the ordinary shares.

 

 

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 2 of 25

 

 

1

NAME OF REPORTING PERSON

 

General Atlantic Singapore Fund Pte. Ltd.

  
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)  ☐

(b)  ☒

3

SEC USE ONLY

 

 

  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Singapore

  

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

 5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

4,782,441

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

4,782,441

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,782,441

  
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 ☐
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.8%

  
12

TYPE OF REPORTING PERSON

 

CO

  

 

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 3 of 25

 

 

1

NAME OF REPORTING PERSON

 

General Atlantic Singapore Interholdco Ltd.

  
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)  ☐

(b)  ☒

3

SEC USE ONLY

 

 

  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Bermuda

  

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

 5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

4,782,441

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

4,782,441

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,782,441

  
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 ☐
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.8%

  
12

TYPE OF REPORTING PERSON

 

CO

  

 

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 4 of 25

 

 

1

NAME OF REPORTING PERSON

 

General Atlantic Partners (Bermuda) IV, L.P.

  
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)  ☐

(b)  ☒

3

SEC USE ONLY

 

 

  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Bermuda

  

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

 5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

4,782,441

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

4,782,441

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,782,441

  
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 ☐
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.8%

  
12

TYPE OF REPORTING PERSON

 

PN

  

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 5 of 25

 

 

1

NAME OF REPORTING PERSON

 

General Atlantic Partners (Bermuda) EU, L.P.

  
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)  ☐

(b)  ☒

3

SEC USE ONLY

 

 

  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Bermuda

  

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

 5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

4,782,441

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

4,782,441

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,782,441

  
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 ☐
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.8%

  
12

TYPE OF REPORTING PERSON

 

PN

  

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 6 of 25

 

 

1

NAME OF REPORTING PERSON

 

General Atlantic GenPar (Bermuda), L.P.

  
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)  ☐

(b)  ☒

3

SEC USE ONLY

 

 

  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Bermuda

  

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

 5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

4,782,441

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

4,782,441

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,782,441

  
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 ☐
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.8%

  
12

TYPE OF REPORTING PERSON

 

PN

  

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 7 of 25

 

 

1

NAME OF REPORTING PERSON

 

GAP (Bermuda) L.P.

  
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)  ☐

(b)  ☒

3

SEC USE ONLY

 

 

  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Bermuda

  

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

 5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

4,782,441

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

4,782,441

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,782,441

  
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 ☐
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.8%

  
12

TYPE OF REPORTING PERSON

 

PN

  

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 8 of 25

 

 

1

NAME OF REPORTING PERSON

 

General Atlantic, L.P.

  
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)  ☐

(b)  ☒

3

SEC USE ONLY

 

 

  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

  

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

 5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

4,782,441

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

4,782,441

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,782,441

  
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 ☐
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.8%

  
12

TYPE OF REPORTING PERSON

 

PN

  

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 9 of 25

 

 

1

NAME OF REPORTING PERSON

 

GAP Coinvestments III, LLC

  
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)  ☐

(b)  ☒

3

SEC USE ONLY

 

 

  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

  

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

 5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

4,782,441

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

4,782,441

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,782,441

  
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 ☐
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.8%

  
12

TYPE OF REPORTING PERSON

 

OO

  

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 10 of 25

 

 

1

NAME OF REPORTING PERSON

 

GAP Coinvestments IV, LLC

  
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)  ☐

(b)  ☒

3

SEC USE ONLY

 

 

  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

  

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

 5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

4,782,441

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

4,782,441

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,782,441

  
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 ☐
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.8%

  
12

TYPE OF REPORTING PERSON

 

OO

  

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 11 of 25

 

 

1

NAME OF REPORTING PERSON

 

GAP Coinvestments V, LLC

  
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)  ☐

(b)  ☒

3

SEC USE ONLY

 

 

  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

  

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

 5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

4,782,441

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

4,782,441

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,782,441

  
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 ☐
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.8%

  
12

TYPE OF REPORTING PERSON

 

OO

  

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 12 of 25

 

 

1

NAME OF REPORTING PERSON

 

GAP Coinvestments CDA, L.P.

  
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)  ☐

(b)  ☒

3

SEC USE ONLY

 

 

  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

  

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

 5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

4,782,441

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

4,782,441

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,782,441

  
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 ☐
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.8%

  
12

TYPE OF REPORTING PERSON

 

PN

  

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 13 of 25

 

 

1

NAME OF REPORTING PERSON

 

General Atlantic Partners (Lux) SCSp

  
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)  ☐

(b)  ☒

3

SEC USE ONLY

 

 

  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Luxembourg

  

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

 5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

4,782,441

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

4,782,441

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,782,441

  
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 ☐
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.8%

  
12

TYPE OF REPORTING PERSON

 

PN

  

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 14 of 25

 

 

1

NAME OF REPORTING PERSON

 

General Atlantic GenPar (Lux) SCSp

  
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)  ☐

(b)  ☒

3

SEC USE ONLY

 

 

  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Luxembourg

  

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

 5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

4,782,441

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

4,782,441

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,782,441

  
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 ☐
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.8%

  
12

TYPE OF REPORTING PERSON

 

PN

  

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 15 of 25

 

 

1

NAME OF REPORTING PERSON

 

General Atlantic (Lux) S.à r.l.

  
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)  ☐

(b)  ☒

3

SEC USE ONLY

 

 

  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Luxembourg

  

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

 5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

4,782,441

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

4,782,441

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,782,441

  
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 ☐
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.8%

  
12

TYPE OF REPORTING PERSON

 

CO

  

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 16 of 25

 

 

1

NAME OF REPORTING PERSON

 

General Atlantic Singapore AI Pte. Ltd.

  
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a)  ☐

(b)  ☒

3

SEC USE ONLY

 

 

  
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Singapore

  

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

 5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

4,782,441

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

4,782,441

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,782,441

  
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

 ☐
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

8.8%

  
12

TYPE OF REPORTING PERSON

 

CO

  

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 17 of 25

 

 

ITEM 1. (a) Name of Issuer
     
 

Adagene Inc.

     
  (b) Address of Issuer’s Principal Executive Offices
     
 

4F, Building C14, No. 218,
Xinghu Street, Suzhou Industrial Park
Suzhou, Jiangsu Province, 215123
People's Republic of China

   
ITEM 2. (a) Name of PersonS Filing
     
 

This statement is being filed on behalf of each of the following persons (collectively, the “Reporting Persons”).

     
  (i) General Atlantic Singapore Fund Pte. Ltd. (“GASF”);
     
  (ii) General Atlantic Singapore Interholdco Ltd. (“GAS Interholdco”);
     
  (iii) General Atlantic Partners (Bermuda) IV, L.P. (“GAP Bermuda IV”);
     
  (iv) General Atlantic Partners (Bermuda) EU, L.P. (“GAP Bermuda EU”);
     
  (v) General Atlantic GenPar (Bermuda), L.P. (“GenPar Bermuda”);
     
  (vi) GAP (Bermuda) L.P. (“GAP (Bermuda) LP”);
     
  (vii) General Atlantic, L.P. (“GA LP”);
     
  (viii) GAP Coinvestments III, LLC (“GAPCO III”);
     
  (ix) GAP Coinvestments IV, LLC (“GAPCO IV”);
     
  (x) GAP Coinvestments V, LLC (“GAPCO V”);
     
  (xi) GAP Coinvestments CDA, L.P. (“GAPCO CDA”);
     
  (xii) General Atlantic Partners (Lux) SCSp (“GAP Lux”);
     
  (xiii) General Atlantic GenPar, (Lux) SCSp (“GA GenPar Lux”);
     
  (xiv) General Atlantic (Lux) S.à. r.l. (“GA Lux”); and
     
  (xv) General Atlantic Singapore AI Pte. Ltd. (“GA AI”).
   
  GAP Bermuda IV, GAP Bermuda EU, GAP Lux, GAPCO III, GAPCO IV, GAPCO V and GAPCO CDA are collectively referred to as the “GA Funds.”

 

 

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 18 of 25

 

 

  (b) Address of Principal Business Office, or if none, Residence
     
 

The address of GA LP, GAPCO III, GAPCO IV, GAPCO V, and GAPCO CDA is c/o General Atlantic Service Company, L.P., 55 East 52nd Street, 33rd Floor, New York, NY 10055. The address of GAS Interholdco, GAP Bermuda IV, GAP Bermuda EU, GenPar Bermuda, and GAP (Bermuda) LP is C/O Conyers Client Services Limited, Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. The address of GAP Lux, GA GenPar Lux and GA Lux Sarl is 412F, route d’Esch, L-2086 Luxembourg, Grand Duchy of Luxembourg. The address of GASF and GA AI is 80 Robinson Road #02-00, Singapore, 068898.

     
  (c) Citizenship
     
  (i) GASF - Singapore
     
  (ii) GAS Interholdco - Bermuda
     
  (iii) GAP Bermuda IV - Bermuda
     
  (iv) GAP Bermuda EU - Bermuda
     
  (v) GenPar Bermuda - Bermuda
     
  (vi) GAP (Bermuda) LP - Bermuda
     
  (vii) GA LLC - Delaware
     
  (viii) GAPCO III - Delaware
     
  (ix) GAPCO IV - Delaware
     
  (x) GAPCO V - Delaware
     
  (xi) GAPCO CDA - Delaware
     
  (xii) GAP Lux - Luxembourg
     
  (xiii) GA GenPar Lux - Luxembourg
     
  (xiv) GA Lux - Luxembourg
     
  (xv) GA AI - Singapore

 

 

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 19 of 25

 

 

  (d) Title of Class of Securities
     
 

Ordinary shares, par value US$0.0001 per share (“ordinary shares”).

 

The Issuer’s American Depositary Shares (the “ADSs”), evidenced by American Depositary Receipts, each representing one and one quarter (1.25) ordinary shares, are listed on the Nasdaq Global Select Market under the symbol “ADAG.”

     
  (e) CUSIP Number
     
 

005329107*

*This CUSIP applies to the ADSs, evidenced by American Depositary Receipts, each representing one and one quarter (1.25) ordinary shares. No CUSIP has been assigned to the ordinary shares.

     
ITEM 3.

IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS:

     
  Not Applicable.
   
ITEM 4.

OWNERSHIP

   
  As of December 31, 2021, the Reporting Persons owned the following number of ordinary shares:

 

  (i) GASF owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
     
  (ii) GAS Interholdco owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
     
  (iii) GAP Bermuda IV owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
     
  (iv) GAP Bermuda EU owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
     
  (v) GenPar Bermuda owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
     
  (vi) GAP (Bermuda) LP owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
     
  (vii) GA LP owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
     
  (viii) GAPCO III owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.

 

 

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 20 of 25

 

 

  (ix) GAPCO IV owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
     
  (x) GAPCO V owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
     
  (xi) GAPCO CDA owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
     
  (xii) GAP Lux owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
     
  (xiii) GA GenPar Lux owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
     
  (xiv) GA Lux owned of record no ordinary shares and no ADSs representing ordinary shares, or 0.0% of the issued and outstanding ordinary shares.
     
  (xv) GA AI owned of record 4,452,441 ordinary shares and 264,000 ADSs representing 330,000 ordinary shares, or approximately 8.8% of the issued and outstanding ordinary shares.

 

 

GA AI is wholly owned by GASF. The majority shareholder of GASF is GAS Interholdco. The members of GAS Interholdco that share beneficial ownership of the ordinary shares and ADSs held of record by GA AI are the GA Funds. The general partner of GAP Lux is GA GenPar Lux and the general partner of GA GenPar Lux is GA Lux. The general partner of GAP Bermuda EU and GAP Bermuda IV and the sole shareholder of GA Lux is GenPar Bermuda. GAP (Bermuda) LP, which is controlled by the Management Committee of GASC MGP, LLC (the “GA Management Committee”), is the general partner of GenPar Bermuda. GA LP, which is also controlled by the GA Management Committee, is the managing member of GAPCO III, GAPCO IV and GAPCO V and the general partner of GAPCO CDA. There are nine members of the GA Management Committee as of the date hereof. Each of the members of the GA Management Committee disclaims ownership of the ordinary shares, the ADSs and the underlying ordinary shares except to the extent that he has a pecuniary interest therein. The name, the business address and the citizenship of each of the members of the GA Management Committee and the directors of GASF and GAS Interholdco, in each case as of the date hereof, is attached hereto as Schedule A and is hereby incorporated by reference.

 

Amount Beneficially Owned:

By virtue of the relationship described above, each of the Reporting Persons may be deemed to beneficially own 4,452,441 ordinary shares and 264,000 ADSs representing 330,000 ordinary shares.

 

Percentage Owned:

All calculations of percentage ownership herein are based on an aggregate of 54,397,383 ordinary shares of the Issuer reported to be outstanding as of March 31, 2021, as reflected in the Issuer’s Annual Report on Form 20-K, filed with the U.S. Securities and Exchange Commission on April 28, 2021.

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 21 of 25

 

 

  Number of Shares as to Which Such Person Has Sole/Shared Power to Vote or to Direct the Vote and Sole/Shared Power to Dispose or to Direct the Disposition of:
  (i) Each of the Reporting Persons may be deemed to have the sole power to direct the voting and dispositions of the ordinary shares, the ADSs and underlying ordinary shares as indicated on such Reporting Person’s cover page included herein.
     
  (ii) Each of the Reporting Persons may be deemed to share the power to direct the voting and dispositions of 4,452,441 ordinary shares and 264,000 ADSs representing 330,000 ordinary shares that may be deemed to be owned beneficially by each of them.

 

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
   
  Not Applicable.
   
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
   
  Not Applicable.
   
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
   
  Not Applicable.
   
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
   
 

See Item 4, which states the identity of the members of the group filing this Schedule 13G.

   
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
   
  Not Applicable.
   
ITEM 10. CERTIFICATION
   
  Not Applicable.

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 22 of 25

 

 

Exhibit Index

 

Exhibit 1: Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

 

 

 

 

 

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 23 of 25

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 11, 2022

 

  GENERAL ATLANTIC SINGAPORE FUND PTE. LTD.  
       
  By: /s/ Ong Yu Huat  
  Name: Ong Yu Huat  
  Title: Director  
       
     
  GENERAL ATLANTIC SINGAPORE INTERHOLDCO LTD.  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Director  
       
     
  GENERAL ATLANTIC PARTNERS (BERMUDA) IV, L.P.  
     
 

By:

General Atlantic GenPar (Bermuda), L.P., its General Partner

  
     
 

By:

GAP (Bermuda) L.P., its General Partner

  
     
  By: GAP (Bermuda) GP Limited, its General Partner  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Managing Director  
       
     
  GENERAL ATLANTIC PARTNERS (BERMUDA) EU, L.P.  
     
 

By:

General Atlantic GenPar (Bermuda), L.P., its General Partner

  
     
 

By:

GAP (Bermuda) L.P., its General Partner

  
     
  By: GAP (Bermuda) GP Limited, its General Partner  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Managing Director  
       
       
  GENERAL ATLANTIC GENPAR (BERMUDA), L.P.  
     
 

By:

GAP (Bermuda) L.P., its General Partner

  
     
  By: GAP (Bermuda) GP Limited, its General Partner  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Managing Director  
       
     
  GAP (BERMUDA) L.P.  
       
 

By:

GAP (Bermuda) GP Limited, its general partner

  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Managing Director  

 

  

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 24 of 25

 

 

  GENERAL ATLANTIC, L.P.  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Managing Director  
       
     
  GAP COINVESTMENTS III, LLC  
     
  By: General Atlantic, L.P., its Managing Member  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Managing Director  
       
     
  GAP COINVESTMENTS IV, LLC  
     
  By: General Atlantic, L.P., its Managing Member  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Managing Director  
       
     
  GAP COINVESTMENTS V, LLC  
     
  By: General Atlantic, L.P., its Managing Member  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Managing Director  
       
     
  GAP COINVESTMENTS CDA, L.P.  
     
  By: General Atlantic, L.P., its General Partner  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Managing Director  

 

 

 

 

CUSIP No. 005329107 SCHEDULE 13G Page 25 of 25

 

 

  GENERAL ATLANTIC PARTNERS (LUX) SCSP  
     
 

By:

General Atlantic GenPar (Lux) SCSp, its General Partner

  
       
  By: General Atlantic (Lux) S.à r.l., its General Partner  
       
  By: /s/ Ingrid van der Hoorn  
  Name: Ingrid van der Hoorn  
  Title: Manager A  
       
  By: /s/ Gregor Dalrymple  
  Name: Gregor Dalrymple  
  Title: Manager B  
     
     
  GENERAL ATLANTIC GENPAR, (LUX) SCSP  
     
  By: General Atlantic (Lux) S.à. r.l., its General Partner  
       
  By: /s/ Ingrid van der Hoorn  
  Name: Ingrid van der Hoorn  
  Title: Manager A  
       
  By: /s/ Gregor Dalrymple  
  Name: Gregor Dalrymple  
  Title: Manager B  
     
     
  GENERAL ATLANTIC (LUX) S.À R.L.  
     
  By: /s/ Ingrid van der Hoorn  
  Name: Ingrid van der Hoorn  
  Title: Manager A  
       
  By: /s/ Gregor Dalrymple  
  Name: Gregor Dalrymple  
  Title: Manager B  
     
     
  GENERAL ATLANTIC SINGAPORE AI PTE. LTD.  
     
  By: /s/ Ong Yu Huat  
  Name: Ong Yu Huat  
  Title: Director  

 

  

 

 

SCHEDULE A

Members of the GA Management Committee (as of the date hereof)

Name Address Citizenship

William E. Ford

(Chief Executive Officer)

55 East 52nd Street

33rd Floor

New York, New York 10055

 United States
Gabriel Caillaux

23 Savile Row

London W1S 2ET

United Kingdom

 France
Andrew Crawford

55 East 52nd Street

33rd Floor

New York, New York 10055

 United States
Martin Escobari

55 East 52nd Street

33rd Floor

New York, New York 10055

 Bolivia and Brazil
Anton J. Levy

55 East 52nd Street

33rd Floor

New York, New York 10055

 United States
Sandeep Naik

Asia Square Tower 1

8 Marina View, #41-04

Singapore 018960

 United States
Graves Tompkins

55 East 52nd Street

33rd Floor

New York, New York 10055

 United States
N. Robbert Vorhoff

55 East 52nd Street

33rd Floor

New York, New York 10055

 United States
Eric Zhang

Suite 5704-5706, 57F

Two IFC, 8 Finance Street

Central, Hong Kong, China

 Hong Kong SAR

 

 

 

 

Directors of General Atlantic Singapore Fund Pte. Ltd.

(as of the date hereof)

Name Address Citizenship
Ong Yu Huat

Asia Square Tower 1

8 Marina View, #41-04

Singapore 018960

 Singapore

Izkander Edward Heylett

Asia Square Tower 1

8 Marina View, #41-04

Singapore 018960

 Malaysia

 

Directors of General Atlantic Singapore Interholdco Ltd.

(as of the date hereof)

Name Address Citizenship
Michael Gosk

55 East 52nd Street

33rd Floor

New York, New York 10055

 United States
Christopher G. Lanning

55 East 52nd Street

33rd Floor

New York, New York 10055

 United States

 

 

 

 

EXHIBIT 1

 

JOINT ACQUISITION STATEMENT

PURSUANT TO RULE 13D-1(k)(1)

 

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is accurate.

 

February 11, 2022

 

  GENERAL ATLANTIC SINGAPORE FUND PTE. LTD.  
       
  By: /s/ Ong Yu Huat  
  Name: Ong Yu Huat  
  Title: Director  
       
     
  GENERAL ATLANTIC SINGAPORE INTERHOLDCO LTD.  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Director  
       
     
  GENERAL ATLANTIC PARTNERS (BERMUDA) IV, L.P.  
     
 

By:

General Atlantic GenPar (Bermuda), L.P., its General Partner

  
       
 

By:

GAP (Bermuda) L.P., its General Partner

  
       
  By: GAP (Bermuda) GP Limited, its General Partner  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Managing Director  

 

 

 

 

  GENERAL ATLANTIC PARTNERS (BERMUDA) EU, L.P.  
     
 

By:

General Atlantic GenPar (Bermuda), L.P., its General Partner

  
     
  By: GAP (Bermuda) L.P., its General Partner  
     
 

By:

GAP (Bermuda) GP Limited, its General Partner

  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Managing Director  
       
       
  GENERAL ATLANTIC GENPAR (BERMUDA), L.P.  
     
 

By:

GAP (Bermuda) L.P., its General Partner

  
     
  By: GAP (Bermuda) GP Limited, its General Partner  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Managing Director  
       
     
  GAP (BERMUDA) L.P.  
       
 

By:

GAP (Bermuda) GP Limited, its General Partner

  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Managing Director  
       
     
  GENERAL ATLANTIC, L.P.  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Managing Director  

 

 

 

 

 

  GAP COINVESTMENTS III, LLC  
     
  By: General Atlantic L.P., its Managing Member  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Managing Director  
       
     
  GAP COINVESTMENTS IV, LLC  
     
  By: General Atlantic, L.P., its Managing Member  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Managing Director  
       
     
  GAP COINVESTMENTS V, LLC  
     
  By: General Atlantic, L.P., its Managing Member  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Managing Director  
       
     
  GAP COINVESTMENTS CDA, L.P.  
     
  By: General Atlantic, L.P., its General Partner  
       
  By: /s/ Michael Gosk  
  Name: Michael Gosk  
  Title: Managing Director  

 

 

 

 

  GENERAL ATLANTIC PARTNERS (LUX) SCSP  
     
 

By:

General Atlantic GenPar (Lux) SCSp, its General Partner

  
     
  By: General Atlantic (Lux) S.à r.l., its General Partner  
       
  By: /s/ Ingrid van der Hoorn  
  Name: Ingrid van der Hoorn  
  Title: Manager A  
       
  By: /s/ Gregor Dalrymple  
  Name: Gregor Dalrymple  
  Title: Manager B  
     
     
  GENERAL ATLANTIC GENPAR, (LUX) SCSP  
     
  By: General Atlantic (Lux) S.à. r.l., its General Partner  
       
  By: /s/ Ingrid van der Hoorn  
  Name: Ingrid van der Hoorn  
  Title: Manager A  
       
  By: /s/ Gregor Dalrymple  
  Name: Gregor Dalrymple  
  Title: Manager B  
     
     
  GENERAL ATLANTIC (LUX) S.À R.L.  
     
  By: /s/ Ingrid van der Hoorn  
  Name: Ingrid van der Hoorn  
  Title: Manager A  
       
  By: /s/ Gregor Dalrymple  
  Name: Gregor Dalrymple  
  Title:

Manager B

  
     
     
  GENERAL ATLANTIC SINGAPORE AI PTE. LTD.  
     
  By: /s/ Ong Yu Huat  
  Name: Ong Yu Huat  
  Title: Director  

 

 

 
Get the next $ADAG alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ADAG

DatePrice TargetRatingAnalyst
1/31/2025Overweight → Equal-Weight
Morgan Stanley
2/1/2022$27.00 → $15.00Overweight
Morgan Stanley
More analyst ratings

$ADAG
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

    Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses SAFEbody technology utilized to create masked T cell engagers for potentially superior safety profile with enhanced therapeutic index Cash balance of $85.2 million provides runway into late 2026 SAN DIEGO and SUZHOU, China, March 24, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel anti-body-based therapies, today reported financial results for the full year 2024 and provided corporate updates. "The clinica

    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

    SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its presentation at the 11th Annual Immuno-Oncology 360⁰ Summit in Boston on March 26, 2025. The summit, designed for all-size pharma/biotech companies, academia and investors seeking to enable a patient's immune ​​​​system to eradicate cancer, provides the opportunity to hear directly from science and business stakeholders on the latest data impacting the field of immuno-oncology. Immuno-Oncology 360⁰ Summit Title: ADG126 SAFEbody®: Targeting CTLA-4+ Tregs to Overcome MSS CRC

    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Adagene to Present at Leerink's Global Healthcare Conference 2025

    SAN DIEGO and SUZHOU, China, March 06, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will participate in one-on-one investor meetings and provide a corporate update at Leerink's Global Healthcare Conference 2025, taking place March 10-12 in Miami, Florida. Leerink's Global Healthcare Conference 2025 Presentation Date: Wednesday, March 12Presentation Time: 10:40-11:20 AM (Eastern Time)Location: W South Beach A webcast of the presentation will be accessible in the Investors

    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ADAG
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ADAG
 SEC Filings

See more

$ADAG
 Leadership Updates

Live Leadership Updates

See more

  • Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

    - Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy - SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the "SAB"). Dr. Lenz is the Associate Director for Clinical Research and Co-leader of the Translational Science Program at the USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC and Co-Director of the Center for Cancer Drug Development a

    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board

    - Brings deep insight in tumor-specific Treg depletion for anti-CTLA-4 therapies delivered intratumorally to overcome dose dependent toxicities - - Expertise contributes to Adagene's novel anti-CTLA-4 therapies delivered systemically at higher and repeated doses with compelling safety - SAN DIEGO and SUZHOU, China, March 05, 2023 (GLOBE NEWSWIRE) --  Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Professor Aurélien Marabelle, MD, PhD, to its Scientific and Strategic Advisory Board (the "SAB"). Professor Marabelle is a physician-scientist with expertise in oncology and imm

    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Adagene Appoints Cuong Do to Board of Directors and Audit Committee

    SAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Cuong Do, MBA, to Adagene's board of directors (the "Board") as an independent director. He will also serve as an audit committee member. Mr. Do is President and CEO of BioVie Inc., a clinical-stage company developing innovative therapies for Alzheimer's Disease, Parkinson's disease and refractory Ascites. Prior to BioVie, Mr. Do was President of Samsung's Global Strategy Group where he helped to set the strategic direction for Samsung Group's diverse business portfolio, i

    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ADAG
 Financials

Live finance-specific insights

See more

  • Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates

    – Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be presented at SITC 2022 – – Masked, anti-CTLA-4 antibody, ADG126, safely dosed repeatedly up to 20 mg/kg as a single agent with encouraging efficacy signals; results to be presented at ESMO 2022 – – Presentation of combination dosing data with anti-PD-1 therapies in 2022, while dose expansion begins for both ADG116 and ADG126 in targeted tumors – – Submitted regulatory filing for clinical trial of masked, IgG1-based anti-CD137 candidate, ADG206, with greater preclinical potency than the analog of

    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ADAG
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more